Merck & Company Inc (MRK)vsVarex Imaging Corp (VREX)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
VREX
Varex Imaging Corp
$11.03
-8.62%
HEALTHCARE · Cap: $505.97M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 7509% more annual revenue ($65.01B vs $854.40M). MRK leads profitability with a 28.1% profit margin vs -7.9%. MRK appears more attractively valued with a PEG of 3.36. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
VREX
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+68.1%
Fair Value
$42.68
Current Price
$11.03
$31.65 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Reasonable price relative to book value
Earnings expanding 453.4% YoY
Conservative balance sheet, low leverage
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
4.9% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : VREX
The strongest argument for VREX centers on Price/Book, EPS Growth, Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : VREX
The primary concerns for VREX are Revenue Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
MRK profiles as a value stock while VREX is a turnaround play — different risk/reward profiles.
VREX carries more volatility with a beta of 1.00 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 50/100), backed by strong 28.1% margins. VREX offers better value entry with a 68.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Varex Imaging Corp
HEALTHCARE · MEDICAL DEVICES · USA
Varex Imaging Corporation designs and manufactures X-ray imaging components. The company is headquartered in Salt Lake City, Utah.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?